Thalidomide in relapsed or refractory multiple myeloma: How much and for how long?

被引：3

作者：

Abdalla, SH

Mahmoud, S

机构：

[1] Imperial Coll Fac Med, London W2 1PG, England

[2] St Marys NHS Trust, London W2 1NY, England

来源：

LEUKEMIA & LYMPHOMA | 2003年 / 44卷 / 06期

关键词：

thalidomide; myeloma; dose; duration;

D O I：

10.1080/1042819031000068016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The optimum dose and duration of treatment with thalidomide for relapsed or refractory multiple myeloma are not known. Long term responses were seen in 5 patients given low doses of thalidomide (100-200 mg) with or without pulsed dexamethasone, for between 48 and 108 weeks. The responses were sustained for between 23 and 67 weeks after stopping treatment. We recommend that the lowest effective dose (LED) and optimum duration of therapy with thalidomide should be determined within the framework of a well conducted clinical trial in order to answer these important questions.

引用

页码：989 / 991

页数：3

共 50 条

[41] A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
Prince, HM
Mileshkin, L
Roberts, A
Ganju, V
Underhill, C
Catalano, J
Bell, R
Seymour, JF
Westerman, D
Simmons, PJ
Lillie, K
Milner, AD
Di Iulio, J
Zeldis, JB
Ramsay, R
CLINICAL CANCER RESEARCH, 2005, 11 (15) : 5504 - 5514
[42] The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma
R García-Sanz
J R González-Porras
J M Hernández
M Polo-Zarzuela
A Sureda
C Barrenetxea
L Palomera
R López
C Grande-García
A Alegre
M Vargas-Pabón
O N Gutiérrez
J A Rodríguez
J F San Miguel
Leukemia, 2004, 18 : 856 - 863
[43] Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Iida, Shinsuke
Wakabayashi, Masashi
Tsukasaki, Kunihiro
Miyamoto, Kenichi
Maruyama, Dai
Yamamoto, Kazuhito
Takatsuka, Yoshifusa
Kusumoto, Shigeru
Kuroda, Junya
Ando, Kiyoshi
Kikukawa, Yoshitaka
Masaki, Yasufumi
Kobayashi, Miki
Hanamura, Ichiro
Asai, Hiroaki
Nagai, Hirokazu
Shimada, Kazuyuki
Tsukamoto, Norifumi
Inoue, Yoshiko
Tobinai, Kensei
CANCER SCIENCE, 2018, 109 (05) : 1552 - 1561
[44] Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma
Murakami, Hirokazu
Shimizu, Kazuyuki
Sawamura, Morio
Suzuki, Kenshi
Sugiura, Isamu
Kosugi, Hiroshi
Shimazaki, Chihiro
Taniwaki, Masafumi
Abe, Masahiro
Takagi, Toshiyuki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (05) : 636 - 641
[45] OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma
Kropff, Martin
Baylon, Honorata Giongco
Hillengass, Jens
Robak, Tadeusz
Hajek, Roman
Liebisch, Peter
Goranov, Stefan
Hulin, Cyrille
Blade, Joan
Caravita, Tomaso
Avet-Loiseau, Herve
Moehler, Thomas M.
Pattou, Claire
Lucy, Lela
Kueenburg, Elisabeth
Glasmacher, Axel
Zerbib, Robert
Facon, Thierry
BLOOD, 2009, 114 (22) : 396 - 396
[46] CarfilzomibIn Relapsed, or Relapsed and Refractory, Multiple Myeloma
Paul L. McCormack
Drugs, 2012, 72 : 2023 - 2032
[47] Carfilzomib In Relapsed, or Relapsed and Refractory, Multiple Myeloma
McCormack, Paul L.
DRUGS, 2012, 72 (15) : 2023 - 2032
[48] Therapy of relapsed and relapsed refractory multiple myeloma
Driessen, C.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 113 - 113
[49] Management of Relapsed and Relapsed/Refractory Multiple Myeloma
Laubach, Jacob P.
Mitsiades, Constantine S.
Mahindra, Anuj
Luskin, Marlise R.
Rosenblatt, Jacalyn
Ghobrial, Irene M.
Schlossman, Robert L.
Avigan, David
Raje, Noopur
Munshi, Nikhil C.
Anderson, Kenneth C.
Richardson, Paul G.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (10): : 1209 - 1216
[50] Long term response and survival after thalidomide in relapsed/wrefractory multiple myeloma
Zappasodi, P.
Corso, A.
Barbarano, L.
Brasca, P.
Petrucci, M. T.
Calabrese, E.
Palumbo, A.
Bringhen, S.
Pascutto, C.
Mangiacavalli, S.
Varettoni, M.
Pica, G. M.
Lazzarinu, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 137 - 137

← 1 2 3 4 5 →